IP Library Granted Patent US 10,583,225
Granted Patent B2
US 10,583,225 · App. 16/444,170 · Granted Mar 10, 2020

Method of coating scoring or cutting balloon catheters

Inventors: Ulrich Speck (Berlin, DE); Madeleine Caroline Berg (Berlin, DE)
Assignee: ANGIOSCORE, INC.
A61L29/08A61B17/320725A61L29/143A61L29/16A61L31/16A61M25/10A61M25/104A61B2017/320733A61L2300/216A61L2300/416A61L2300/606A61L2300/802A61M2025/105A61M2025/109
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,225
App. No.
16/444,170
Granted
Mar 10, 2020
Kind
B2
Abstract

The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one oxidation-insensitive drug or oxidation-insensitive polymer free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiaretic acid, resveratrol and propyl gallate.

Claims (33)

1. A method of manufacturing a medical device for use in angioplasty or coronary angioplasty, comprising:

providing a balloon catheter, the balloon catheter comprising:

a shaft;

an inflatable balloon coupled to the shaft; and

a nonimplantable scoring structure surrounding the inflatable balloon; and

spraying a coating composition onto at least a portion of a surface of the balloon catheter, wherein the coating composition comprises a therapeutically effective amount of at least one oxidation-insensitive drug and an amount of nordihydroguaiaretic acid, wherein the nordihydroguaiaretic acid protects the at least one oxidation-insensitive drug from premature loss during delivery to an angioplasty site, wherein the amount of nordihydroguaiaretic acid is 3-100% by weight of the at least one oxidation-insensitive drug, wherein the at least one oxidation-insensitive drug is selected from the group consisting of: taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids.

2. The method according to claim 1 , wherein the nonimplantable scoring structure comprises one or more wires capable of scoring a luminal surface of a blood vessel upon inflation of the inflatable balloon.

3. The method according to claim 1 , wherein the coating composition is sprayed onto the inflatable balloon.

4. The method according to claim 1 , wherein the at least one oxidation-insensitive drug is a taxane selected from the group consisting of paclitaxel, protaxel and docetaxel.

5. The method according to claim 4 , wherein the taxane is paclitaxel.

6. The method according to claim 1 , wherein the amount of nordihydroguaiaretic acid includes up to 10 μg/mm 2 of the surface of the inflatable balloon.

7. The method according to claim 1 , wherein the amount of nordihydroguaiaretic acid is at a ratio of 20-100% by weight, in relation to 100% by weight of the at least one oxidation-insensitive drug.

8. The method according to claim 1 , wherein the amount of nordihydroguaiaretic acid is at a ratio of 50-100% by weight, in relation to 100% by weight of the at least one oxidation-insensitive drug.

9. The method according to claim 1 , wherein the coating composition is polymer-free.

10. A method of manufacturing a medical device for use in angioplasty or coronary angioplasty, comprising:

providing a balloon catheter, the balloon catheter comprising:

a shaft;

an inflatable balloon coupled to the shaft, wherein the inflatable balloon has a surface; and

a nonimplantable cutting structure surrounding the inflatable balloon; and

spraying a coating composition onto at least a portion of the surface of the inflatable balloon, wherein the coating composition comprises a therapeutically effective amount of at least one oxidation-insensitive drug and an amount of nordihydroguaiaretic acid capable of protecting the at least one oxidation-insensitive drug from premature loss during delivery to an angioplasty site, wherein the nordihydroguaiaretic acid is 3-100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected from the group consisting of: taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids.

11. The method according to claim 10 , wherein the at least one drug comprises oxidation-insensitive paclitaxel.

12. A method of manufacturing a medical device for use in angioplasty or coronary angioplasty, comprising:

providing a balloon catheter, the balloon catheter comprising:

a shaft;

an inflatable balloon coupled to the shaft, wherein the inflatable balloon has a surface; and

a nonimplantable scoring structure surrounding the inflatable balloon; and

spraying a coating composition onto at least a portion of the surface of the inflatable balloon, wherein the coating composition comprises a therapeutically effective amount of an oxidation-insensitive taxane drug and an amount of nordihydroguaiaretic acid that protects the oxidation-insensitive taxane drug from premature loss during delivery to an angioplasty site, wherein the nordihydroguaiaretic acid is at a ratio of 20-100% by weight, in relation to 100% by weight of the oxidation-insensitive taxane drug.

13. The method according to claim 12 , wherein the scoring structure comprises one or more wires capable of scoring a luminal surface of a blood vessel upon inflation of the inflatable balloon.

14. The method according to claim 12 , wherein the oxidation-insensitive taxane drug is selected from the group consisting of paclitaxel, protaxel and docetaxel.

15. The method according to claim 14 , wherein the amount of nordihydroguaiaretic acid comprises up to 10 μg/mm 2 of the surface of the inflatable balloon.

16. The method according to claim 12 , wherein the oxidation-insensitive taxane is paclitaxel.

17. The method according to claim 16 , wherein the amount of nordihydroguaiaretic acid comprises up to 10 μg/mm 2 of the surface of the inflatable balloon.

18. The method according to claim 12 , wherein the amount of nordihydroguaiaretic acid comprises up to 10 μg/mm 2 of the surface of the inflatable balloon.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2023
From: ANGIOSCORE LLC
To: SPECTRANETICS LLC
Reel/Frame 062627/0559 →